Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthorStephenLurieMD, PhDIndividualAuthor
Copyright 1999 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.1999
In Reply: We acknowledge that the article by
Dr Bennett and colleagues first highlighted the underappreciated association
of TTP with ticlopidine1 and acknowledge
the preliminary report as a letter of the incidence of TTP after stenting.
However, based on the available data, we do not think it is prudent to speculate
that 2 weeks of treatment is safer than 4 weeks. Although only 21% of our
patients with TTP were treated for no more than 2 weeks, this may just reflect
an overall smaller percentage of patients treated for 2 weeks. That 15% of
the patients discussed in their published series developed TTP within 2 weeks
highlights that the occurrence of this syndrome may not be as rare as they
Steinhubl SR, Tan WA, Foody JM, Topol EJ. Ticlopidine and TTP After Coronary Stenting—Reply. JAMA. 1999;282(18):1717-1719. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-18-jbk1110